The Food and Drug Administration approved the first pill to treat postpartum depression in adults, whose symptoms can range from sadness and loss of energy to cognitive impairment and suicidal ideation. Patients would take the drug (Zurzuvae) for 14 days. The only other approved treatment is an intravenous injection.

“Having access to an oral medication will be a beneficial option for many of these women coping with extreme, and sometimes life-threatening, feelings,” said Tiffany Farchione, M.D., director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research. 

Centers for Disease Control and Prevention research shows that about 1 in 8 women experience symptoms of postpartum depression and that the rate of depression diagnoses at delivery is increasing.

The AHA recently released an infographic that highlights how hospitals can help support maternal mental health.

Headline
A new AHA toolkit offers practical strategies to strengthen rural maternal care, drawing on insights from 160 leaders representing 92 hospitals and health…
Headline
The Department of Health and Human Services Nov. 12 made two announcements  regarding the development of mental health treatments for veterans and other…
Headline
A study on substance-related emergency department visits and hospitalizations published Nov. 4 by The American Journal of Psychiatry found that cannabis was…
Headline
The Food and Drug Administration Oct. 29 issued a proposed rule to update infant formula nutrient requirements, the first such update since 1998. The proposal…
Headline
Extending Medicaid coverage by 12 months following childbirth increased use of postpartum care among mothers with pregnancy complications such as diabetes and…
Headline
The AHA has released its latest downloadable Fast Facts infographic providing statistics on the number of behavioral health hospitals and hospital services in…